Abstract: Herpes zoster (Hz), which generally presents as a localized, painful cutaneous eruption, is a common clinical problem, particularly among adults $ 50 years of age and immunocompromised patients. The diagnosis of Hz is mainly made clinically, except in patients with atypical manifestations or certain complications, such as central nervous system involvement, in which laboratory virologic testing is required. In addition to having a higher mortality rate, immunocompromised individuals have atypical and severe clinical findings and are at greater risk for complications and recurrence of Hz. Treatment of Hz includes the use of antiviral agents, analgesics for control of acute zoster pain, good skin care for healing, and prevention of secondary bacterial infection. Antiviral agents, preferably valacyclovir or famciclovir, should be started within 72 hours of onset to reduce the severity of the infection, the duration of the eruptive phase, and the intensity of acute pain. Herpes zoster has been associated with several complications, of which post-herpetic neuralgia (PHN) is the most common and debilitating. Varicella-zoster virus vaccine and early treatment with either famciclovir or valacyclovir are the only measures proven to prevent PHN. The options for treating PHN include topical agents, such as lidocaine patches, and systemic agents, such as the anticonvulsants gabapentin and pregabalin. Measures for preventing Hz include infection control through routine hand hygiene and appropriate use of isolation precautions and personal protective equipment; immunoglobulins, such as the varicella-zoster virus immunoglobulin and vaccine; and antiviral agents. The zoster vaccine has been shown to be effective in reducing the incidence of Hz and PHN. The vaccine is recommended for all individuals aged $ 60 years who have no contraindications, including individuals who report a previous episode of Hz.
Introduction
Herpes zoster (Hz), or shingles, results from reactivation of varicella-zoster virus (VZV) infection. Varicella-zoster virus is one of the alphaherpesviruses that initially infect somatic cells (mucoepithelial) . Replication in these cell types is then followed by the transmission of viral infection into the neurons. Viral particles enter at the termini of the sensory neurons of the peripheral nervous system and then transport long distances along axons in the retrograde direction toward cell bodies, where the genomes are deposited into the nucleus to establish lifelong latency. The virus establishes latency in cells of the cranial nerve, dorsal root, and autonomic ganglia. Latency is characterized by the presence of viral DNA in ganglionic neurons, with limited virus gene transcription. Following reactivation from latency, new viral particles are assembled and spread in the anterograde direction back out toward the periphery, producing the characteristic bandlike rash in the involved dermatome. Rarely, viral particles spread trans-synaptically from the neurons of the peripheral nervous system into higher-order neurons of the central nervous system (CNS). 1, 2 Primary infection with varicella stimulates VZV antibody production and activates VZV-specific T cells, which control later stages of reactivation. Varicellazoster virus occasionally reactivates due to a decline in the specific cell-mediated immunity to VZV with aging, immunosuppression (due to diseases with immune system dysfunction or drugs that suppress the immune system), or both. Herpes zoster occurs equally in men and women and without seasonal variation. Although it usually occurs once during a lifetime, second episodes may occur in immunocompromised individuals and, rarely, in immunocompetent individuals. 3 The incidence of Hz ranges from 1.5 to 4 cases per 1000 persons per year, with up to 1 million new cases per year in the United States. The incidence of Hz increases with aging; the incidence in individuals aged . 75 years has reached up . 10 to 12 cases per 1000 person-years. More than 50% of cases of Hz occur in individuals aged $ 60 years. 4, 5 In approximately 10% to 20% of individuals with Hz, herpes zoster ophthalmicus (HZO) may develop. A retrospective, population-based cohort study among patients enrolled in a US private health plan reported that the overall incidence of HZO was 30.9 per 100 000 person-years, and for the population aged $ 65 years, the incidence was 104.6 per 100 000 person-years, approximately 5-fold that of the rest of the population. 6 The incidence of Hz is also high in individuals with certain medical conditions (Table 1) . [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Recent literature indicates that the prevalence of Hz and its complications (eg, disseminated disease and ocular, neurologic, and visceral organ involvement) are decreasing in patients with human immunodeficiency virus (HIV), probably due to immune system improvement with combination antiretroviral therapy. A retrospective cohort study reported that the Hz incidence rate during the study period (2002-2009) was 9.3 new Hz cases per 1000 personyears of follow-up, whereas between 1997 and 2001, the incidence rate was 32 new Hz cases per 1000 person-years of follow-up. The incidence of Hz and its complications in HIV-infected individuals are still higher than those in the general population. Low CD4 cell counts and detectable viral loads have been associated with an increased risk for Hz. Individuals with HIV are at high risk for immune reconstitution syndrome on starting combination antiretroviral therapy. [17] [18] [19] 
Clinical Manifestation
The clinical presentation of Hz varies widely, ranging from localized cutaneous dermatomal involvement to visceral organ involvement, including the CNS and the eyes (Table 2) . Herpes zoster often manifests spontaneously. An age-matched casecontrol study using Medicare claims data found that patients with Hz were 3.4-fold (95% CI, 2.8-4.2) as likely as controls to have experienced trauma in the week before Hz onset. The association was even stronger in cranial zoster, in which patients were 27.5-fold (95% CI, 5.4-140.3) more likely than controls to have had cranial trauma in the week before Hz onset. 20 Cutaneous Hz is characterized by the eruption of an erythematous maculopapular rash, followed by the appearance of clear vesicles and new vesicle formation for 3 to 5 days, followed by pustulation and scabbing of the lesion. Skin lesions usually heal within 2 to 4 weeks, often leaving skin scarring and permanent changes in pigmentation. The lesions, which appear in the skin segment innervated by a single sensory ganglion (dermatome), are unilateral and do not cross the midline. However, simultaneous involvement of . 1 dermatome, contiguous or noncontiguous, and lesions crossing the midline may occur in immunocompromised patients, but virtually never in immunocompetent individuals. The most frequently involved dermatomes are thoracic, followed by cranial (especially trigeminal), lumbar, and cervical. Acute pain from the Hz-involved dermatome ranges from mild itching, tingling, or allodynia (pain provoked by light touch) to severe pain. It occurs in $ 95% of patients aged . 50 years, and 60% to 70% of patients continue to have persistent pain 1 month after the episode. Patients with cutaneous Hz may have low-grade fever, headache, photophobia, and malaise before eruption of the rash. The rash is sometimes preceded by paresthesia, itching, and pain for 1 to 5 days, a condition termed pre-herpetic neuralgia (PHN). 18 Differential diagnoses for Hz include acute herpes simplex, contact dermatitis, impetigo, folliculitis, scabies, insect bites, drug-induced rash, and varicella infection. Herpes simplex can sometimes present in a band that mimics a dermatome (zosteriform herpes simplex), which should be considered in the differential diagnosis in patients with recurrent localized, grouped vesicles, especially involving the mouth or genital regions. 22 There are several Hz-associated neurologic complications, such as PHN, meningitis, meningoencephalitis, cerebellitis, isolated cranial nerve palsies, that produce ophthalmoplegia or the Ramsay Hunt syndrome, Bell's palsy, multiple cranial nerve palsies (polyneuritis cranialis), vasculopathy, myelitis, acute disseminated encephalomyelitis, acute inflammatory demyelinating polyneuropathy (Guillain-Barré syndrome), focal motor weakness, and various inflammatory disorders of the eye, the most serious of which is acute retinal necrosis (Table 2) . [23] [24] [25] [26] [27] [28] [29] Subclinical invasion of VZV into the CNS is relatively common; approximately one third and 46% of neurologically asymptomatic immunocompetent individuals with cutaneous Hz have a cerebrospinal fluid (CSF) polymerase chain reaction test result that is positive for VZV and CSF leukocytosis, respectively. 30 Post-herpetic neuropathy, the most common complication of Hz, is defined as a neuropathic pain that persists for . 3 months after the complete resolution of the cutaneous lesions of Hz. The pathogenesis of PHN is unknown but may be due to either the excitability of ganglionic or spinal cord neurons or persistent low-grade infection resulting from viral invasion of the nerve roots, with subsequent inflammation and destruction. 20 The prevalence of PHN increases with aging and other risk factors and ranges from 5% to 22% (Table 3) . [31] [32] [33] [34] Post-herpetic neuropathy can persist from a few months to years. The pain of PHN can manifest as burning, throbbing, an episodic sharp electric shock-like sensation, tactile allodynia, or hyperalgesia (exaggerated response to a painful stimulus). It is associated with long-term psychological distress and physical disabilities that lead to loss of workdays, interference with sleep and daily activities, and loss of quality of life. It is also associated with a substantial health care cost. 34 
Diagnosis
The diagnosis of Hz is based on the characteristic cutaneous eruption (a vesicular rash that follows a defined dermatomal pattern and is accompanied by neuropathic pain). The clinical diagnosis of cutaneous Hz may not be obvious, particularly in immunocompromised patients, and may mimic other cutaneous diseases, such as herpes simplex virus (HSV) infection, drug reaction, and contact dermatitis. not conforming to a dermatomal distribution, or persistent neuropathic pain without the appearance of typical skin lesions. Laboratory testing is also required in patients with CNS and visceral organ involvement and zoster sine herpete ( Table 2 ). Confirmatory testing includes direct fluorescent antigen assay, viral culture, or quantitative polymerase chain reaction for the detection of VZV DNA in skin lesion/ visceral organ samples, whereas polymerase chain reaction of body fluids such as CSF, along with antibody testing (immunoglobulin G) for VZV in CSF, are first-choice tests in patients with suspected CNS and visceral organ involvement. 35 The advantages of direct fluorescent antigen (which involves staining cells that have been scraped from the base of the lesions with a scalpel blade using fluorescein-conjugated monoclonal antibodies) are that it is more sensitive than viral culture and it can distinguish between HSV and VZV. 36 A thorough history and physical examination should be performed in all patients with Hz to identify risk factors such as underlying malignancy or immunodeficiency. However, routine additional laboratory and imaging studies should not be performed unless otherwise clinically indicated. An agebased cancer screening should be performed in patients with Hz (eg, a yearly mammogram is recommended in all women starting at age 40 years). 37, 38 Herpes zoster is more common among HIV-infected individuals, particularly among young adults, compared with age-matched individuals in the general population. Therefore, adults with a new diagnosis of Hz should be screened for HIV by undergoing an assessment for risk factors and serologic testing. 19 
Treatment
The primary objectives of the treatment of Hz are to soothe and protect the involved skin, accelerate the healing of skin lesions, reduce the duration of zoster-associated pain (defined as pain from the onset until resolution), prevent bacterial superinfection, and improve patients' functioning and quality of life.
Determining whether a patient can be treated safely as an outpatient or requires hospitalization is the first essential step in the treatment of Hz. Patients with severe, disseminated infection, severe herpes zoster ophthalmicus with ocular involvement, or visceral involvement such as CNS, should be hospitalized for therapy with intravenous acyclovir and supportive care. 22, 23 Soothing and protecting the involved skin can be achieved using compresses and a sterile, occlusive, nonadherent protective dressing. The skin lesions should be kept clean and dry to reduce the risk for bacterial superinfection.
It is recommended that treatment with antiviral agents be started in patients with Hz who present within 72 hours of lesion onset. Initiating treatment with antiviral agents within 72 hours of lesion onset results in shorter duration of viral shedding and new lesion formation, reduction of the duration of zoster-associated acute pain, and acceleration of cutaneous healing. 39 However, antiviral agents can still be prescribed in certain patients who present . 72 hours after lesion onset. These patients include older adults ($ 60 years of age) with severe pain and a large area of skin involvement; immunocompromised patients; those with continued new vesicle formation; and those with visceral, neurologic, or ocular complications, including HZO. In approximately 50% of patients with HZO, ocular complications will develop if antiviral treatment is not administered. 40 Therapy with antiviral agents has been reported to reduce the frequency of late ocular inflammatory complications such as keratopathy, episcleritis, iritis, and stromal keratitis in patients with HZO. [41] [42] [43] Acyclovir, valacyclovir, and famciclovir have been approved in the United States for the treatment of Hz (Table 4) . They are all effective for the treatment of Hz, although the latter 2 drugs are preferred because of a simplified dosing schedule, improved pharmacokinetic characteristics, and superiority to acyclovir in the reduction of herpes zoster-associated pain and PHN duration in immunocompetent adults aged $ 50 years. 41, 44 Oral antiviral agents are commonly used for the treatment of uncomplicated Hz. Intravenous acyclovir should be used for the treatment of disseminated Hz; severe HZO; and ocular, visceral organ, and CNS involvement. 23 Topical acyclovir or penciclovir should not be used for the treatment of any type of Hz infection, except as therapy adjuvant to systemic antiviral agents for corneal epithelial disease. 23 In a large, nationwide cohort study from Denmark that included 1804 pregnancies, exposure to acyclovir, famciclovir, or valacyclovir in the first trimester of pregnancy was not associated with an increased risk for major birth defects. 45 One of the essential elements of the treatment of Hz is adequate control of both acute Hz-related pain and chronic pain associated with PHN. Controlling acute Hz-related pain not only will improve functional status and healthrelated quality of life but also will reduce the risk for PHN. Only treatment with amitriptyline, ganglion blockade with bupivacaine and dexamethasone, and repetitive epidural injection of methylprednisolone acetate and bupivacaine during the acute illness has been reported to prevent PHN in clinical trials. [46] [47] [48] The use of systemic corticosteroids has not been reported to prevent PHN in clinical trials, but it reduced the duration of acute neuritis, as measured by a reduced need for analgesics and by a more rapid return to usual activities and uninterrupted sleep. Therefore, it is recommended that a 10-to 14-day tapering course of oral prednisone (eg, starting at 60 mg/d) be added to a regimen of antiviral agents in patients with Hz who are aged . 50 years, have moderate to severe pain at presentation, and have no contraindications for its use. [49] [50] [51] Acute Hz-related pain can be controlled with the use of a short-acting narcotic analgesic agent (eg, oxycodone) given on a scheduled rather than on an as-needed basis, a 5% lidocaine patch, gabapentin or amitriptyline in addition to oral analgesic agents, oral prednisone in addition to an antiviral agent and an analgesic agent, an epidural injection of methylprednisolone acetate and bupivacaine (once or repetitive) in addition to an oral analgesic agent, ganglion blockade with bupivacaine and dexamethasone, and/or acupuncture. Topical capsaicin should not be used in patients with active Hz because it can exacerbate pain, but it can be used for the treatment of PHN. 48, 49, [52] [53] [54] [55] [56] [57] The management of PHN often requires a multifaceted therapeutic approach due to symptoms that vary in nature and severity, a long disease duration, and a potential for psychological and physical debilitation. Options for the treatment of PHN are summarized in Table 5 . In cases of uncontrolled pain or intolerable adverse effects with monotherapy, combination therapy may be required. [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] In addition to drug therapies, several other modalities have been employed to treat PHN. These modalities include invasive interventions such as sympathetic nerve blocks, intercostal nerve block, pulsed radiofrequency, intrathecal injection of methylprednisolone acetate, spinal cord stimulation, cryotherapy, botulinum toxin A injection, acupuncture, and transcutaneous electrical nerve stimulation.
70-77
Prevention Varicella-zoster virus can be transmitted from a person with Hz to a person who is VZV seronegative, resulting in varicella. The virus can be transmitted through direct contact with lesions from a patient with dermatomal Hz. It can also be transmitted through the airborne route, particularly from patients with disseminated Hz. Patients should be isolated until all lesions are crusted. Most authorities recommend standard precautions and the use of gloves when touching the lesions of patients with localized Hz. Severely immunocompromised patients in whom dermatomal Hz has developed should be placed on both airborne and contact isolation until it is clear that dissemination is not developing.
All patients with disseminated Hz should be placed in airborne and contact isolation. 78 Patients with active Hz should be especially careful to avoid contact with infants and small children, pregnant women, and immunocompromised individuals, all of whom are potentially susceptible. Health care workers, family members, household contacts, and visitors who are healthy and who do not have a reported history of varicella infection or who are VZV seronegative should receive varicella vaccination before any direct contact with recipients of a peripheral blood stem cell transplant (PBSCT) or a solid organ transplant (SOT). The vaccination schedule should be completed at least 4 weeks before PBSCT. While undergoing conditioning therapy, PBSCT recipients should avoid contact with any VZV vaccine recipient who experiences a rash after vaccination. than among those aged $ 70 years; however, it prevented PHN to a greater extent among adults aged $ 70 years. 13, [80] [81] [82] [83] [84] The vaccine was found to be less effective in untreated, depressed individuals than in nondepressed and depressed individuals treated with antidepressant medications. 13 The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention recommends that the VZV vaccine be given as a single 0.65-mL dose subcutaneously in the deltoid region of the arm in immunocompetent adults aged $ 60 years, regardless of history of varicella infection. 85 Serologic testing for past exposure is not required prior to vaccination. In 2011, the US Food and Drug Administration expanded the age indication for the VZV vaccine to include adults aged 50 to 59 years. Although the protection of VZV vaccine declines gradually, a booster dose is not recommended. 86 The vaccine is effective through year 5 after vaccination, and the postvaccination antibody concentrations are similar after either 1 or 2 doses of the vaccine. 87, 88 Because it is a live vaccine, VZV is contraindicated in people with active, untreated tuberculosis; pregnant women; in immunocompromised adults, such as those with leukemia, lymphoma, or advanced malignancy; and in patients receiving chemotherapy, radiotherapy, and large doses of corticosteroids. The vaccine also should not be given to persons with a history of anaphylactic reaction to any vaccine components, such as gelatin and neomycin. Antiviral agents such as acyclovir should not be used for at least 24 hours before and 14 days after vaccination. 89 The vaccine is effective and well tolerated in older adults (aged $ 60 years) taking anti-tumor necrosis factor or other biologic therapies, in individuals with hematologic malignancies (in remission), and in PBSCT recipients. 90, 91 However, live vaccines should not be given to PBSCT recipients who are , 24 months post-transplantation, who still require immunosuppressive therapy, or who have evidence of graftversus-host disease (GVHD). 92 The vaccine is well tolerated. Common adverse effects are injection-site reaction, itching, and headache. The vaccine can be given concurrently with influenza and pneumococcal vaccines in older adults without altering the immune response to either vaccine. 93, 94 Despite reported efficacy, and despite being recommended by the ACIP since 2006, the VZV vaccine is still underutilized, particularly among minority groups such as Hispanic patients and non-Hispanic black patients. 95 The cost-effectiveness of the vaccine is affected mainly by age at vaccination, incidence of Hz, price and duration of protection of the vaccine, and duration of PHN. The vaccine is likely to be cost-effective if the duration of protection is . 10 years. 96 Herpes zoster reactivates commonly in certain immunocompromised patients, particularly in PBSCT recipients, and it is associated with a high risk for PHN. 97, 98 Long-term prophylaxis with low-dose oral acyclovir (400-800 mg/d) or valacyclovir (2000 mg/d) for the prevention of recurrent VZV infection is routinely recommended for the first year after transplantation in VZV-seropositive, allogeneic and autologous PBSCT recipients and in patients with multiple myeloma receiving bortezomib-based therapy. [99] [100] [101] [102] [103] Patients with multiple myeloma treated with bortezomib and who are undergoing long-term acyclovir prophylaxis are at increased risk for severe renal and neurologic toxicity. Therefore, renal function and neurologic condition should be closely monitored. 104 In allogeneic PBSCT recipients who have chronic GVHD or who require systemic immunosuppression at persistent risk for VZV reactivation, the optimal duration of prophylaxis is poorly defined. Prophylaxis with acyclovir or valacyclovir is commonly continued until, or 6 months after, the discontinuation of all systemic immunosuppressive drugs and until CD4 count reaches . 200 cells/mm 3 . Prophylaxis should be restarted with the resumption of systemic immunosuppressive drugs for either rejection or GVHD.
In SOT recipients, prophylaxis for cytomegalovirus (CMV) with valganciclovir, ganciclovir, acyclovir, or valacyclovir also prevents VZV reactivation. SOT recipients not receiving prophylaxis for CMV prevention but who are HSV-1 or HSV-2 seropositive are usually undergoing lowdose acyclovir prophylaxis (for $ 1 month), which prevents VZV reactivation. However, the risk for VZV reactivation persists for years after SOT, and prophylaxis with antiviral agents is unlikely to prevent the majority of cases of Hz. Starting antiviral agents once Hz develops is a practical option after the discontinuation of CMV or HSV prophylaxis. 99 In SOT candidates who are VZV seronegative and who have no contraindications for the use of live attenuated varicella vaccine, 2 doses of the vaccine should be administered, with a minimum interval of 4 to 6 weeks between the 2 doses, and with the second dose given $ 2 weeks (and preferably . 4 weeks) prior to transplantation. Seroprotection should be confirmed after vaccination, with consideration of subsequent doses in patients who do not respond to the initial series. 105 Any individual exposed to a potential case of contagious varicella or Hz (household contact, face-to-face contact) should have a thorough assessment that includes status of the source, the exposure itself, and the exposed person's susceptibility to the infection and risk for severe infection. Evidence of immunity to varicella in adults includes any of the following: documentation of 2 doses of varicella vaccine $ 4 weeks apart; history of varicella or Hz based on diagnosis by a health care provider; serologic evidence of either immunity or disease; or birth in the United States before 1980, except in health care workers and pregnant women. 86 Nonimmune, immunocompetent, exposed individuals should be given varicella vaccine as early as possible, and up to 5 days after exposure. Administration of varicella vaccine within the first few days after exposure to wild-type VZV produces a protective (or partially protective) immune response. The ACIP recommends that, during an outbreak of varicella, all nonimmune, immunocompetent individuals be given the first or second dose of varicella vaccine, provided that the appropriate interval has elapsed (3 months in individuals aged 12 months to 12 years and $ 4 weeks in individuals aged $ 13 years). 106 However, in exposed pregnant women and in immunocompromised individuals, live varicella or VZV vaccine is contraindicated. These groups of individuals should receive passive immunization with varicella-zoster immunoglobulin (VZIG) 125 U per 10 kg (maximum, 625 U; minimum, 125 U) as a deep intramuscular injection within 10 days of the exposure. If VZIG is unavailable, intravenous immunoglobulin 400 mg/kg should be given. In immunocompromised, susceptible individuals, postexposure prophylaxis with antiviral agents can be used as an adjuvant to immunoprophylaxis with VZIG, or alone if VZIG is either unavailable or cannot be used. Acyclovir or valacyclovir should be given from days 3 to 22 after known exposure to either varicella or Hz, and from days 3 to 28 if given with immunoprophylaxis. 107 All exposed, susceptible individuals should undergo airborne and contact precautions from days 10 to 21 after exposure to the index case, and those who receive VZIG should undergo precautions until day 28.
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